Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
OVERALL SURVIVAL NOT YET REACHED; 57% OF PATIENTS CONTINUE TO BE FOLLOWED
CYTRX PLANS TO DISCUSS PIVOTAL TRIAL DESIGN WITH THE FDA
I agree with all of your points but am having a hard time getting over the fact that this stock continues to s__t the bed. Yes, it's partially due to market conditions but if it really has so much going for it, how come it's low $2s with so many catalysts lined up? The concept of buy low, sell high just doesn't seem to be happening here otherwise we'd be seeing some serious accumulation happening. I thought we'd be seeing this trending up the last few months of last year into this year and continuing, but it's doing the complete opposite.
I also don't believe in manipulation and being held down nonsense for big boys to accumulate. The simple fact is that nobody is buying this. CYTR and management have killed credibility of the company, no matter how good the pipeline potential is and unless they provide stellar, out-of-this-world clinical results this will continue.
Steve K. is a slimy pile of s__t. I still stand behind the belief that the share price of this company would be north of $5 if that #$%$ wasn't in charge of this company. His shady involvement in the whole GALE situation casts a large cloud of doubt over CYTR and it's going to take a long time to move past that, if we ever do until he steps down. The more he stays in the shadows the better, but I doubt he's smart enough to realize that.
I thought I was the only one continually lowering expectations with this company. Good to know I have company.
Let's just wait and see what kind of ridiculousness happens over night to pull us back down again. What a rigged, manipulated pos market.
The dude has sway. If it can't make moves on positive news something is wrong. Management's reputation continues to kill the potential here, imo.
We never thought they'd do an offering this low but they just did it a few months ago at a severe discount to where the share price actually was. I think it was around 3.75 or so and they offered at 2.75. Doesn't exactly inspire confidence. I'm with telmeafbl lately. There's something fundamentally wrong here when a stock is heavily shorted at 52-week lows. He's right, shorts are much more savvy than longs and they continue to pile on. It doesn't matter what news comes out of this stock it continues to act like a pig.
Last year we were all looking forward to the many catalysts lined up this year but it's abundantly clear that they're not going to matter much. Until this company is through FDA approval and selling product, it's going to languish.
I'm hoping that after todays congressional hearing on drug pricing policy, we move past the current pain we've been seeing in bios. I don't think we'll be seeing rosy days like we have seen in the past few years, but hopefully we can move back to some companies being properly, fair valued.
I gotta agree, something is coming after hours and it won't be pretty. Count on CYTR to issue bad news on a Friday afternoon.
I never pay attention to analyst targets. I can't remember the last time one of them was accurate. They're the equivalent of a weatherman. One moment it's sunny, the next moment it's raining. It's two jobs I can think of where you can be wrong 100% of the time and keep your job.
Being a low float and all, it's been hit pretty hard lately and sitting at unfair levels, imo. There's not much volume lately, which is a tad surprising, but I think that's partly due to many not willing to jump back into bios yet. It's hard to believe we're sitting well under insider buy prices and the recent secondary price. Fundamentals have not changed here and we are still looking at a catalyst per quarter, through the first three quarters. Let's hope it's strong enough to drive up the price substantially if we're still in current bear market conditions.
I also liked how he mentioned that. Increasing the space and headcount. I also like how he talked up the new hires.